Aspirin and Colorectal Cancer

A daily dose moderate discharge of the long taken term aspirin can prevent the colorectal cancer, but gastroenterologists is cautious on the recommendation of him, investigating said.

Five years of a daily dose of aspirin of magnesium 300 or the colorectal occurrence above reduced to 63% to 74% of the cancer, disclosed Peter M. Rothwell, M.D., Ph.D., of the infirmary of Radcliffe here, and colleagues the results of its 10 - to the recordativa letter of 14 years of two great British tests to support the studies of short term observation that measure risk of the adenoma, they wrote in the application of the 12 of May the Lancet. But, the results contradict those of great, long term studies of aspirin under the dose, such as the study of the health of the doctors and the study of the health of the women. The difference is probable because one more a higher dose is necessary to affect the formation of the adenoma via the way cyclo-oxygenase-2 (COX-2), wrote to Andrew T. Chan, M.D., M.P.H., of the general hospital of Massachusetts in Boston, in a support editorial. “Nevertheless, with the preoccupations by the potential risks of the long term use of aspirin and the availability of the alternative strategies of the prevention (eg., defending), these results are not sufficient to authorize a recommendation for the population in general to use aspirin for the prevention of the cancer,” the Dr noticed Chan. The Dr Rothwell and colleagues followed in two British tests that began in early years 80. British doctors Aspirin Trial originally included 5,139 masculine doctors at random selected to aspirin of 500 magnesium or to no aspirin by five to six years. They did not blind to the participants to the treatment. The isquémico attack transitory Aspirin BRITON of test (UK-TIA) included 2,449 patients who who'd had a recent AUNT or a isquémico movement of smaller importance. They at random selected to the patients aspirin of magnesium 300 to magnesium or 1,200 to the day or placebo by an a seven years depending on the date of randomization. The investigators used national registries of the cancer to follow the colorectal occurrence of the cancer for a midpoint of 23 years in both tests. Altogether, there were 215 boxes colorectal of the cancer. Between the reunited results of the analysis: Any use of aspirin of the duration in the tests reduced the colorectal occurrence of the cancer (quotient of the danger interval 0,56 to 0,97 of the 0,74 confidence, of 95%, P=0.02). Five or more years of use of aspirin reduced occurrence still more (hour ci 0,47 to 0,85 of 0,63, of 95%, P=0.002). The effect only appeared after 10 years (hour 0,92 by the first nine years, P=0.73, against 0,60 by 19 years 10 to, P=0.007). The greatest advantage was considered after five or more years of aspirin it uses 10 to 14 years after randomization (hour ci 0,20 to 0,70 of 0,37, of 95%, P=0.002), particularly for which they were obedient (hour ci 0,12 to 0,56 of 0,26, of 95%, P=0.0002). There was no effect on the non-colorectal occurrence of the cancer (hour ci 0,88 to 1,16 of 1,01, of 95%, P=0.87). They designed the known investigators, nevertheless, who were no data on use of aspirin after the tests finished and no test to study the colorectal cancer. The investigators also made a systematic revision of studies of observation in the risk of the colorectal cancer with aspirin or other antiinflammatory drugs nonsteroidal (NSAIDs). Between the 19 studies of the marry-control of the independent one including, the majority found less aspirin or use of NSAID between the patients who developed the colorectal cancer (reunited quotient of probabilities ci 0,73 to 0,87 of 0,80, of 95%, P<0.0001). Like in at random selected tests, the revision of Literature demonstrated the advantage of increase for a longer and more frequent use. Aspirin irregular or occasional or the NSAID use conferred no advantage (Or ci 0,93 to 1,09 of 1,01, of 95%, P=0.87). The quotients of the probabilities were 0,79 for the short term use of aspirin defined like less than five or 10 years, 0,69 by five or more or 10 or more years of the therapy, and 0,60 by 10 or more years of regular use. Together, the results suggest aspirin is effective in the primary prevention of the colorectal cancer, the concluded investigators. The “use of magnesium 300 or more of aspirin than to the day by near five years is effective in the primary prevention of the colorectal cancer, with a latency of near 10 years, that are constant with results of observation studies,” wrote. If the high oral doses of aspirin are necessary for this advantage, the “additional investigation on the direct local effects of the low dose colonic-sends preparations could be of merit,” the Dr Rothwell wrote. Whereas the cardiovascular advantages and colorectal of the cancer of aspirin can compensate the risk of bleeding the complications for certain groups of elevated risk, they said, the doctors will need to load this decision for the peace ientes individualmente. “Sin embargo, antes de que el chemoprevention pueda ser práctico, más trabajo es necesario caracterizar los para quién las ventajas potenciales del aspirin compensan los peligros,” el editorialista que el Dr. Chan escribió.